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Background: Rhaponticum cathamoides (RC) is an endemic wild Siberian herb with marked medicinal properties
that are still poorly understood. The aim of this study is to investigate the therapeutic potential of RC extract (ERC)
compared to the effects of Glycyrrhiza glabra (EGG) and Punica granatum extracts (EPG) in a rat model with high-fat
diet-(HFD)-induced signs of metabolic syndrome; therefore, this study addresses a significant global public health
problem.
Methods: Six-month-old male Wistar Albino Glaxo rats were subjected to eight weeks of a standard diet (SD), HFD,
or HFD in which ERC, EGG, or EPG powders were incorporated at 300 mg/kg/day. The serum lipid profile,
corticosterone and cytokine concentrations, glucose tolerance, systolic blood pressure, triacylglycerol accumulation,
and PPARα DNA-binding activities in the liver samples were determined.
Results: In contrast to EGG and EPG, an ERC supplement significantly reduced the weight of epididymal tissue
(19.0%, p < 0.01) and basal serum glucose level (19.4%, p < 0.05). ERC improved glucose intolerance as well as
dyslipidemia more efficiently than EGG and EPG. EGG but not ERC or EPG supplementation decreased systolic
blood pressure by 12.0% (p < 0.05). All of the tested extracts reduced serum IL6 and corticosterone levels induced
by HFD. However, the lowering effects of ERC consumption on the serum TNF-α level and its restoring effect on
the adrenal corticosterone level significantly exceeded the improvements induced by EGG and EPG. ERC intake also
reduced triacylglycerol accumulation and increased the PPARα DNA-binding activity in the liver more significantly
than EGG and EPG.
Conclusions: ERC powder supplementation improved glucose and lipid metabolism more significantly than EGG
and EPG in rats fed on HFD, supporting the strategy of R. carthamoides use for safe relief of metabolic syndrome
and its related disturbances such as inflammation, stress, and hepatic steatosis.
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Metabolic syndrome, a condition defined by a cluster of
cardiometabolic risk factors including visceral adiposity,
diabetes mellitus, dyslipidemia, and high blood pressure
represents a significant global public health problem [1].* Correspondence: midushkin@soramn.ru
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reproduction in any medium, provided the orAmong environmental factors, the high-fat diet and sed-
entary lifestyle common in the Western world are con-
sidered to be the major causes of obesity-associated
impaired glucose tolerance and dyslipidemia [2]. Meta-
bolic syndrome is also often characterized by chronic in-
flammation and hepatic steatosis [3]. Early treatment of
people with metabolic syndrome may prevent the devel-
opment of cardiovascular disease. Current treatment
strategies include lifestyle modifications with pharmaco-
logical interventions targeted at complex manifestations
of the metabolic syndrome as necessary [4]. Multiplel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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require a simultaneous application of different classes of
drugs such as statins, thiazolidinediones, fibrates, bigua-
nides, sulfonylureas, antihypertensive drugs, and many
others for the attainment of beneficial effect. Although
significant progress has been made in the development
of therapeutic strategies for reducing risk factors for car-
diovascular disease [5-7], the integrated management of
metabolic syndrome is often an elusive goal in practice.
The problem of integrated management of metabolic
syndrome arises due to the long-term use of expensive
medications that sometimes may result in adverse side
effects. Recently, a number of innovative nutritional
strategies based on a long and successful practice have
been proposed as a safe alternative treatments to reduce
the morbidity as well as the cost of metabolic syndrome
treatment [8-10].
To date, more than 1000 officinal plant treatments for
metabolic disorders have been reported, although only a
small number of these have received scientific and med-
ical evaluation to assess their comparative efficacy [11].
Therefore, more screening trials of commercial herbal
products are needed to develop functional as well as
analytical bases for standardization of dietary supple-
ments [12]. Among herbs of this kind, nutritional ingre-
dients of Glycyrrhiza glabra and Punica granatum are
widely used in Indian and Chinese traditional medicine.
The antidiabetic and anti-obesity effects of G. glabra
[13,14] and P. granatum [15,16] are relatively well stud-
ied in animal models. In particular, the licorice flavo-
noids have recently been shown to suppress abdominal
fat accumulation and increase in blood glucose level in
obese rats [17] and mice [18]. High total polyphenol
content is related to antidiabetic and antioxidant effects
of Punica granatum extracts observed in mice [19] and
rats [20].
Rhaponticum carthamoides (Willd) Iljin, commonly
known as maral root or Russian leuzea, has been widely
used in the traditional Siberian medicine, mostly to treat
overstrain and common weakness after illnesses, as a
stimulant, and a remedy against male sex dysfunction.
The principal bioactive constituents of this plant are
ecdysteroids, flavonoids, and phenolic acids. The ex-
tracts and preparations from this plant, which are prac-
tically safe, exhibited various additional antioxidant,
immunomodulatory, antitumor, and antimicrobial effects
[21]. However, relatively scarce literature is available on
the medicinal properties of R. carthamoides as a treat-
ment for metabolic disorders. In addition, the effect of
R. carthamoides, especially on the high fat diet-induced
metabolic syndrome development, remains to be clari-
fied. The potential of R. carthamoides in the inhibition
of the basic manifestations of metabolic syndrome is not
sufficently studied. In the present study, we tested theeffects of the ethanolic extract of R. carthamoides root
versus the commercially available ethanolic extracts of
G. glabra root and P. granatum peel with proclaimed
antidiabetic and anti-obesity properties on the signs of
metabolic syndrome in an obese rat model.
Methods
Plant materials and chemicals
Commercial ethanol extract powder from the root of
R. carthamoides (wild-growing) (20-hydroxyecdisone con-
tent of 2.2% was standardized by HPLC analysis), licorice
root extract powder (glycyrrhizic acid (15.0%) was condi-
tioned by HPLC analysis) and pomegranate peel extract
powder (ellagic acid (40.0%) was conditioned by HPLC ana-
lysis) were obtained from KIT Co., Ltd. (Altai State Tech-
nical University, Barnaul, Russia), Wixi Cima Science Co.,
Ltd. (Jiangsu, China (Mainland)), and Xian Yuensun Bio-
logical Technology Co., Ltd. (Shaanxi, China (Mainland)),
respectively, and were stored at +4°C until use. All other
chemicals were analytical grade.
Animals, diets, and experimental design
Male Wistar Albino Glaxo rats, six months old, were
obtained from the Animal Center of the Institute of
Cytology and Genetics (Novosibirsk, Russia) and were
housed individually in cages in an air-conditioned room
(24.2°C) with a 12 h light/dark cycle and food and water
provided ad libitum. All animal experiments were per-
formed according to the animal ethics guidelines of the
European Communities Council Directive (86/609/EEC)
and approved by the Animal Care Committee of the In-
stitute of Internal Medicine, Novosibirsk, Russia. The
animals were randomly split into 5 groups of 10 rats
each. Group I was maintained on briquette feed standard
diet (SD group) containing 10% fat-derived calories,
while group II was fed a high-fat diet (HFD group)
containing 60% fat-derived calories (Laboratorsnab,
Moscow, Russia) for 8 weeks. The rats of groups III, IV,
and V were fed an HFD supplemented with the powder
extracts of R. carthamoides (ERC group), G. glabra
(EGG group), and P. granatum (EPG group), respect-
ively, at a daily dose of 300 mg/kg of body weight (b.w.)
for 8 weeks. Animals were weighed once a week, and
food intake was measured daily. At the end of each ex-
perimental period, rats were deprived of food for 16 h,
then anesthetized with an intraperitoneal injection of so-
dium pentobarbital (50 mg/kg b.w.) and sacrificed. Epi-
didymal adipose tissue, adrenal gland and liver were
extracted and weighed.
Intraperitoneal glucose tolerance test
At week 8 of the experiment, rats were deprived of food
overnight (16 h) and after collecting a fasting blood sam-
ple from a tail vein were injected intraperitoneally with
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Blood glucose concentration was measured at 60, 120,
and 180 min after injection by One Touch Horizon gluc-
ometer (Lifescan, Johnson and Johnson, NJ, USA).
Blood pressure
At baseline and further weekly, systolic and diastolic
blood pressure were measured by a noninvasive pressure
device using volume pressure recording, CODA 2 (Kent
Scientific, Torrington, CT, USA), on non-anesthetized
rats restrained in the thermic plastic chamber.
Determination of serum triacylglycerol, cholesterol, free
fatty acid, corticosterone, and cytokine content
Blood samples were collected in tubes and centrifuged
at 2400 g. Serum concentration of triacylglycerol (TG),
total cholesterol (TC), and high-density cholesterol
(HDL-C) were measured by an enzymatic colorimetric
method using commercial enzyme assay kits (Olvex
Diagnosticum, St. Petersburg, Russia). Low density lipo-
protein cholesterol (LDL-C) content was calculated
using the formula: LDL-C = TC - (HDL-C + TG/2.2).
Serum concentration of free fatty acid (FFA) was mea-
sured by an enzymatic colorimetric assay according to
the manufacturer’s protocol (free fatty acid, Half-micro
test; Roche Diagnostics, Penzberg, Germany). Serum and
adrenal homogenate corticosterone was assayed by
enzyme-linked immunosorbent assays. Sensitivity limits
were 30 pg/mL and coefficients of variation were 7-9%
using the Enzyme Immunoassay (EIA) kit (Cayman
Chemical, Ann Arbor, MI, USA). Serum tumor necrosis
factor-α (TNF-α) and interleukin-6 (IL-6) levels were
measured by commercially available rat ELISA kits
(eBioscience, CA, USA).
Determination of liver triacylglycerol content
Approximately 0.2 g of hepatic tissue was homogenized
in 0.15 M NaCl solution and extracted using a hexane:
isopropanol mixture (3:2, v/v), containing 0.005% (wt/vol)
butylated hydroxytoluene, according to method of Hara
and Radin [22]. After 10 min centrifugation at 3,000 g and
10°C, the upper organic phase was collected and evapo-
rated under liquid nitrogen. Dry total lipids were resus-
pended in 10% Triton X-100 and isopropanol, and TG
content was measured using a commercial enzyme assay
kit (Olvex Diagnosticum, St. Petersburg, Russia) on an
automatic biochemical analyzer.
Preparation of liver nuclear protein extract
Nuclear protein was isolated according to the method of
Kang et al. [23]. Liver tissue (0.5 g) was homogenized in
a buffer containing 0.32 M sucrose, 10 mM Tris · HCl,
pH 7.4, 1 mM EGTA, 2 mM EDTA, 5 mM NaN3,
10 mM β-mercaptoethanol, 20 μM leupeptin, 0.15 μMpepstatin A, 0.2 mM PMSF, 50 mM NaF, 1 mM sodium
orthovanadate, and 0.4 nM microcystin. The homoge-
nates were centrifuged (1,000 g, 10 min). The pellets
were solubilized in Triton buffer (1% Triton X-100,
150 mM NaCl, 10 mM Tris·HCl, pH 7.4, 1 mM EGTA,
1 mM EDTA, 0.2 mM sodium orthovanadate, 20 μM
leupeptin A, 0.2 mM PMSF). The lysates were centrifuged
(15,000 g, 30 min, 4°C), and the supernatant (nuclear
extract) was stored at −80°C until use. Protein concentra-
tions were estimated using the Bio-Rad (Hercules, CA)
DC protein assay.
Determination of liver PPARα transcription factor activity
PPARα transcription factor activity in liver nuclear ex-
tracts was determined using ELISA-based Cayman
Chemical PPAR-α transcription factor assay kit (Cayman
Chemicals, Ann Arbor, MI, USA) that detects PPAR-α
bound to PPAR response element-containing double-
stranded DNA sequences. Nuclear extract protein sam-
ple (40–50 μg) was used for determination of PPARα
activity using the protocol described in the product
manual, and absorbance was measured at 450 nm.
Statistical analysis
Results are expressed as the means ± standard error (S.E.M.).
Statistical analysis was performed by applying one-way ana-
lysis of variance (ANOVA) followed by the Tukey post hoc
test. Difference between groups was considered significant
at p < 0.05.
Results
Effects on weight of epididymal adipose tissue
No significant differences in body weight and energy in-
take between the groups were observed (data not
shown). Eight weeks after high-fat diet exposure, the
weight of epididymal fat in HFD rats was significantly el-
evated (p < 0.001) compared to the control (SD) rats
(Figure 1). The supplementation of ERC for eight weeks
in the HFD rats significantly lowered the weight of epi-
didymal fat (p < 0.05), whereas supplementation of EGG
or EPG did not alter this characteristic.
Effects on glucose tolerance test and blood lipids
Serum glucose value was increased by 20.0% (p < 0.05)
in HFD rats compared to SD rats (from 4.46 ± 0.16 to
5.34 ± 0.32 mmol/L). The supplementation of ERC, but
not EGG or EPG, significantly reduced basal glucose
levels by 19.4% compared to the HFD group (p < 0.05;
data not shown). An intraperitoneal glucose tolerance
test was performed at the end of week eight of the ex-
periment. The HFD group serum glucose levels were sig-
nificantly higher at 60, 120 and 180 min after glucose
loading compared to the SD group, and all of the three























Figure 1 Epididymal fat tissue weight of rats fed a standard
diet (SD), a high-fat diet (HFD), and an HFD supplemented with
Rhaponticum cathamoides extract (ERC), Punica granatum
extract (EPG) and Glycyrrhiza glabra extract (EGG) (300 mg/kg
per day) for 8 weeks. Data represent the mean ± S.E.M. (n = 10).
The statistical significance of differences between rats fed HFD and
either SD (# p < 0.001) or HFD supplemented with ERC, EPG or EGG
(*p < 0.01) was determined.
Table 1 Serum lipids content (mmol/L) in rats fed
standard diet (SD), high-fat diet (HFD), and HFD
supplemented with Rhaponticum cathamoides extract
(ERC), Punica granatum extract (EPG) and Glycyrrhiza
glabra extract (EGG) (300 mg/kg per day) for 8 weeks
Lipid SD HFD HFD + ERC HD + EGG HFD + EPG
TC 2.03 ± 0.21 2.82 ± 0.24# 2.31 ± 0.19* 2.89 ± 0.32 2.59 ± 0.22
LDL-C 0.47 ± 0.25 1.46 ± 0.35# 0.70 ± 0.24* 1.22 ± 0.34 1.08 ± 0.28*
HDL-C 1.20 ± 0.11 0.81 ± 0.21# 1.11 ± 0.14* 1.08 ± 0.24 0.95 ± 0.22
TG 1.79 ± 0.14 3.27 ± 0.37# 2.53 ± 0.25* 2.45 ± 0.35* 2.82 ± 0.37
FFA 0.76 ± 0.09 1.43 ± 0.24# 1.11 ± 0.12* 1.04 ± 0.12* 1.39 ± 0.16
Data represent the mean ± S.E.M. (n = 10). The statistical significance of
differences between rats fed HFD and either SD (#p < 0.01) or HFD
supplemented with ERC, EPG or EGG (*p < 0.05) was determined.
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the same time, Figure 2 demonstrates that serum glu-
cose levels were significantly lower in rats receiving ERC
(p < 0.05), than in rats receiving EGG or EPG at 120 and
180 min after glucose loading.
As shown in Table 1, the HFD significantly increased the
serum levels of TC (p < 0.001), TG (p < 0.001), LDL-C








































Figure 2 Glucose tolerance test of rats fed standard diet (SD),
high-fat diet (HFD), and HFD supplemented with Rhaponticum
cathamoides extract (ERC), Punica granatum extract (EPG) and
Glycyrrhiza glabra extract (EGG) (300 mg/kg per day) for
8 weeks. Data represent the mean ± S.E.M. (n = 10). The statistical
significance of differences between rats fed HFD and either SD
(#p < 0.001) or HFD supplemented with ERC, EPG or EGG (*p < 0.01),
between rats fed HFD supplemented with ERC and either EPG or
EGG (& p < 0.05) was determined.HDL-C serum content decreased (p < 0.05). The ERC in-
take markedly reduced the serum TG (by 22.6%, p < 0.05),
TC (by 18.0%, p < 0.05), LDL-C (by 52.0%, p < 0.01), and
FFA levels (by 32.4%, p < 0.05) and restored HDL-C level
(by 37.0%, p < 0.05), indicating that ERC reversed the dys-
lipidemia induced by HFD (Table 1). Some improvement in
lipid profiles was also noted for EGG (significant decrease
of TG and FFA content by 25.0 and 27.0%, respectively)
and EPG (significant decrease of LDL-C level by 26.0%)
groups compared to HFD group. The other lipid indicators
in the EGG and EPG groups demonstrated a weak ten-
dency to recovery, albeit not significantly (p > 0.05).
Effects on systolic blood pressure
No significant differences (p>0.05) were observed in sys-
tolic blood pressure of SD and HFD groups. Interest-
ingly, HFD resulted in a tendency to a decreased systolic
blood pressure at the end of week eight (Figure 3), albeit
not significantly (p>0.05). The supplementation of EGG
resulted in a significant decrease of systolic blood pres-
sure by 12.0% (p < 0.05) compared to the HFD group. As
shown in Figure 3, no significant difference was ob-
served upon the supplementation of ERC or EPG in
HFD compared to HFD group.
Effects on serum and adrenal corticosterone
As shown in Figure 4A, the serum corticosterone con-
centration was elevated 2.17-fold in HFD rats compared
to SD rats (p < 0.01). The supplementation of HFD with
ERC and EPG significantly attenuated the rise of cortico-
sterone level by 27.0 and 30.0%, respectively (p < 0.05),
compared to HFD rats, while EGG intake did not signifi-
cantly influence the index. Adrenal corticosterone levels
in the HFD group were 2.15-fold reduced compared to
the SD group (Figure 4B, p < 0.001). As shown in
Figure 4B, ERC restored the corticosterone content in
the adrenal gland by 25.0% (p < 0.05). In contrast, EGG
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Figure 3 Systolic blood pressure of rats fed a standard diet
(SD), a high-fat diet (HFD), and HFD supplemented with
Rhaponticum cathamoides extract (ERC), Punica granatum
extract (EPG) and Glycyrrhiza glabra extract (EGG) (300 mg/kg
per day) for 8 weeks. Data represent the mean ± S.E.M. (n = 10).
The statistical significance of differences between rats fed HFD and
either SD or HFD supplemented with ERC, EPG or EGG (*p < 0.05)
was determined.
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As shown in Figure 5, exposure of rats to an HFD for
eight weeks resulted in 2.7- and 3.1-fold increase of
TNF-α and IL-6 serum content, respectively, compared
to the SD group (p < 0.001). ERC supplementation pre-
vented the HFD-induced elevation of TNF-α serum
level, decreasing its value by 61.6% (p < 0.001). In con-
trast, EGG and EPG reduced the serum TNF-α level to a
lesser extent (by 32.0 and 24.0%, respectively, p < 0.05)
than ERC (Figure 5A). The ERC group significantly dif-
fered from EGG and EPG groups in TNF-α content
(p < 0.05). Figure 5B shows that ERC, EPG, and EGG in-
take resulted in a significant decrease in IL-6 serum level


























Figure 4 Concentration of serum (A) and adrenal (B) corticosterone o
supplemented with Rhaponticum cathamoides extract (ERC), Punica g
(300 mg/kg per day) for 8 weeks. Data represent the mean ± S.E.M. (n =
and either SD (#p < 0.001) or HFD supplemented with ERC, EPG or EGG (*pEffects on liver TG Content, and DNA binding activity of
PPARα
Liver concentration of TG was significantly higher in
HFD rats than in SD rats (p < 0.001). Accumulation of
TG was significantly attenuated by supplementation of
all three studied herb extracts (Figure 6A). However,
ERC was able to reduce liver TG content to a greater ex-
tent (by 49.0% compared to the HFD group, p < 0.01)
than EPG (by 35.0%, p < 0.01) and EGG (by 29.0%,
p < 0.05). TG accumulation was associated with signifi-
cant decline in DNA binding activity of PPARα in liver
of the HFD group compared to the SD group (Figure 6B).
Activation of PPARα is known to improve hepatic lipid
metabolism. Data presented in Figure 6B confirm a sig-
nificant recovery of PPARα DNA binding activity in the
ERC group (by 48.5%, p < 0.01) compared to the HFD
group. In contrast, a minor increase of PPARα DNA
binding activity was observed in rats receiving EGG and
EPG (p > 0.05).
Discussion
Feeding of rats on HFD is a useful tool for the induction
of metabolic syndrome features including distinctive vis-
ceral adiposity, dyslipidemia, impaired glucose tolerance
with diabetes type 2, and hepatic steatosis, which are
typically associated with human obesity. This rat model
of diet-induced obesity is often used to investigate the
effects of metabolic syndrome ameliorating agents, in-
cluding the medicinal plants, as possible sources of new
drugs. Various types of extracts and individual com-
pounds derived from R. carthamoides have been found
to possess a broad spectrum of pharmacological effects
[21,24-27]. However, the possibility that extracts and in-
dividual compounds derived from R. carthamoides may
inhibit the manifestation of metabolic syndrome has


























f rats fed standard diet (SD), high-fat diet (HFD), and HFD
ranatum extract (EPG) and Glycyrrhiza glabra extract (EGG)
10). The statistical significance of differences between rats fed HFD













































Figure 5 Concentration of serum TNF-α (A) and IL-6 (B) of rats fed standard diet (SD), high-fat diet (HFD), and HFD supplemented with
Rhaponticum cathamoides extract (ERC), Punica granatum extract (EPG) and Glycyrrhiza glabra extract (EGG) (300 mg/kg per day) for
8 weeks. Data represent the mean ± S.E.M. (n = 10). The statistical significance of differences between rats fed HFD and either SD (#p < 0.001) or
HFD supplemented with ERC, EPG or EGG (*p < 0.05), between rats fed HFD supplemented with ERC and either EPG or EGG (&p < 0.001)
was determined.
Dushkin et al. BMC Complementary and Alternative Medicine 2014, 14:33 Page 6 of 9
http://www.biomedcentral.com/1472-6882/14/33G. glabra and P. granatum [13-20]. Our comparative
study seems to be the first evidence of the higher poten-
tial of the commercial ethanolic ERC extract, enriched
in 20-hydroxyecdisone, to reduce the weight of epididy-
mal adipose tissue and serum glucose level, to restore
disturbances of serum lipids, corticosterone and inflam-
matory cytokine content in HFD-fed rats, compared to
the commercial ethanolic EGG and EPG extracts, which
enriched in glycyrrhizic acid and ellagic acid, respect-
ively, and are believed to have antidiabetic and anti-
obesity properties. This study also shows that ERC
intake can ameliorate the hepatic steatosis that is associ-
ated with an increased expression of hepatic DNA bind-
ing activity of PPARα.
Supplementation of ERC, EGG and EPG to an HFD rat
(300 mg/kg per day) did not change the body weight of rats
in our experiment. However, the epididymal fat weight was

























Figure 6 Liver triacylglycerol (Liver TG) content (A) and PPARα DNA-b
(HFD), and HFD supplemented with Rhaponticum cathamoides extract
extract (EGG) (300 mg/kg per day) for 8 weeks. Data represent the mea
rats fed HFD and either SD (#p < 0.001) or HFD supplemented with ERC, EP
and either EPG or EGG (&p < 0.05) was determined.study, ERC normalized the plasma glucose level and im-
proved glucose intolerance (Figure 2), decreased LDL-C,
TC, TG, and FFA and increased HDL-C content (Table 1)
to a significantly greater extent than EGG or EPG. In
addition, ERC did not significantly change the systolic
pressure of rats (Figure 3). ERC contains a relatively
high concentration of phytoecdysteroids, mainly, 20-
hydroxyecdysone (2.2% by HPLC data). Diverse extracts
and ecdysteroids derived from R. carthamoides are widely
used in sport medicine as anabolic substances strengthen-
ing biosynthesis in slow muscle fibers. The significant de-
crease of epididymal fat weight without change of body
weight and improvement of glucose intolerance observed
in rats receiving ERC (containing approximately 6.6 mg/kg
per day 20-hydroxyecdysone) are most likely due to the ac-
tivation of the pentose phosphate pathway and utilization
of carbohydrates in protein synthesis stimulated by phy-

































inding activity (B) of rats fed standard diet (SD), high-fat diet
(ERC), Punica granatum extract (EPG) and Glycyrrhiza glabra
n ± S.E.M. (n = 10). The statistical significance of differences between
G or EGG (*p < 0.05), between rats fed HFD supplemented with ERC
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nectin production, as seen in mice fed with an HFD supple-
mented with 10 mg/kg per day 20-hydroxyecdisone [28].
Recent trials in ovariectomized rats also showed that mod-
est doses of 20-hydroxyecdysone (18 mg/day per animal)
increased muscle mass and reduced visceral fat mass, low-
ered serum LDL content, raised serum HDL content, and
did not elevate TG content [29].
Although the hypocholesterolemic action of phytoec-
dysteroids has been demonstrated before [30], the mo-
lecular mechanisms underlying the effects of ERC in
mammals are insufficiently studied. It is known that 20-
hydroxyecdisone is the insect steroid hormone, which
controls lipid metabolism through a specific receptor
complex ecdysone receptor (EcR) [31]. EcRs are ortho-
logs of farnesoid X receptors (FXR) and liver X receptors
(LXR) [32], which play critical roles in the regulation of
lipid metabolism in mammals. Keeping in mind that the
EcR ligand binding domain is similar to the rat FXR and
possesses high homology with LXR [33], it may be as-
sumed that these receptors are the pharmacological tar-
gets of ERC phytoecdysteroids or their metabolites.
Moreover, interaction of LXR with hormone responsive
elements in the promoters of PPAR genes may provide
for the mutual coordination of expression of these tran-
scription factors.
Our finding of the significant beneficial effect of ERC
on hepatic steatosis can be explained by an increase of
PPARα DNA binding activity in liver (Figure 6). Mecha-
nisms of this ERC action remain unclear. We can specu-
late that it is accomplished through direct interaction of
phytosterols with FXR, LXR or other transcription fac-
tors, or indirectly (by changing blood hormonal levels).
In the latter case, promotion of liver PPARα activity may
be interconnected with reduction of insulin level. In-
deed, insulin is known to strongly downregulate the
PPARα mRNA level in rat hepatocytes [34]. Decrease of
insulin level by the action of 20-hydroxyecdisone can
therefore upregulate PPARα and promote its hepatic
activity as observed in the present study. Also, one can-
not exclude that demonstrated hypolipidemic effects
(decrease of serum TG, serum FFA, and liver TG con-
tent) of ERC might be due not only to phytosterols, but
also to the individual or synergistic action of flavonoids
and other active plant phytochemicals.
Considerable evidence from human studies [35,36]
and HFD-fed rodent models [37,38] suggests that in-
creased blood or tissue levels of glucocorticoids and pro-
inflammatory cytokines play a critical role in the devel-
opment of metabolic syndrome. In the present study, we
found that ERC exhibited a significant ability to reduce
serum corticosterone content and restore its adrenal
content (Figure 4), as well as to decrease the HFD-
induced serum TNF-α and IL-6 levels (Figure 5), whileEGG and EPG exhibited significantly less activity of that
kind. Our observations agree with the data obtained in
cultured HeLa cells in which ERC efficiently inhibited
nuclear factor kappa B (NF-κB) [25] involved in cellular
responses to inflammatory stimuli and stress. Interest-
ingly, 20-hydroxyecdisone inhibited NF-κB activation
less efficiently than ERC [25], indicating the presence of
the other anti-inflammatory compounds in ERC, which
are more active, than 20-hydroxyecdisone.
While R. carthamoides contains natural and low toxicity
compounds [21], ERC elicited excellent outcomes without
inducing side effects such as diarrhea, and in the present
study, none of the animals died in the course of experiment
(data not shown). In this emerging context, there are case
reports in the literature that suggest that extensive intake of
licorice may cause development of hypokalemia, edema,
hypertension, and thrombocytopenia [39]. Ellagic acid (up
to 40.0% in studied EPG) could induce a hypercoagulation
state in mice, rats, and rabbits [40]. Moreover, the ellagic
acid-rich pomegranate extracts have a serious drawback of
being unstable in aqueous solutions [41].
Thus, complex action of ERC ethanolic extract exceeds
the compensatory effects of EGG and EPG ethanolic ex-
tracts upon the metabolic syndrome cluster, and, thus,
ERC can be proposed for the use as an efficient thera-
peutic option for the patients who refuse a low-fat diet
for treatment of metabolic syndrome.
Conclusions
Our findings obtained with an HFD rat model suggest that
ERC may prevent and ameliorate the signs of metabolic
syndrome as a result of the complex beneficial effects on
abdominal obesity, glucose intolerance, dyslipidemia, hepa-
tosis, corticosterone and pro-inflammatory cytokine con-
tent with no visible signs or symptoms of toxicity in rats
indicating a high margin of safety. The extract of R. cartha-
moides roots exhibited complex beneficial activity, which
exceeded that of the commercial ethanolic extracts of
G. glabra roots and P. granatum plant enriched in glycyr-
rhizic acid and ellagic acid, respectively, with proclaimed
antidiabetic and anti-obesity properties. Accordingly, ex-
tract of R. carthamoides traditionally used mainly as a re-
storative substance is expanded by data from this study
supporting evidence that natural ingredients of R. cartha-
moides are promising candidates for drug and food con-
stituents to prevent or ameliorate the most prevalent
manifestation of lifestyle-related cluster diseases caused by
an extensively HFD.
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